Month: September 2026

New facility expected to expand capacity by approximately CAD $250 million annually, with potential for approximately CAD $400 million upon full site build-out

GUELPH, Ontario, Sept. 22, 2026 (GLOBE NEWSWIRE) — Hammond Power Solutions Inc. (“HPS” or “Company”; TSX: HPS.A), a leading provider of magnetic and power electronic solutions, announced that it has signed a long-term lease for a new manufacturing facility in Fort Worth, Texas. The facility will expand HPS’s ability to serve U.S.-based customers requiring large standard and custom-engineered transformers. The Fort Worth facility is strategically located to improve proximity to key customers, shorten delivery distances for certain products and enhance HPS’s ability to serve core end markets.

“HPS has built a strong manufacturing platform through its operations in Canada and Mexico, and those facilities will continue to be an important part of how we serve the North American market. This new investment in a U.S. facility is about being closer to our customers and better positioned to support the long-term demand we are seeing for our products,” said Adrian Thomas, Chief Executive Officer of HPS. “Demand for transformers continues to increase, particularly from large projects tied to data centres, electrification and power infrastructure. The Fort Worth facility gives us additional capacity in the U.S. to improve responsiveness, support shorter delivery distances for certain customers, and help us continue to provide the reliability and service our customers expect from HPS.”

Production activities at the facility are expected to commence in stages beginning in Q4 2027. Once the initial production phase commences, the facility is expected to add approximately CAD $250M of manufacturing capacity, based on anticipated demand and normal course operating assumptions. HPS expects to invest approximately CAD $50 million to equip and commission the initial production phase, which it anticipates funding through its existing cash and credit facilities.

The facility was selected, in part, because of its potential to support additional capacity over time. Subject to market demand, future capital investment and other relevant factors, the site could support total annual manufacturing capacity of approximately CAD $400 million.

“Over the past several years, we have made significant investments to enhance efficiency, throughput and capacity across our manufacturing operations in Canada and Mexico,” said John Bailey, Chief Operations Officer of HPS. “The Fort Worth facility provides an opportunity to apply the operational disciplines, manufacturing processes and lessons learned from those investments in a purpose-built environment designed to support future growth. The facility will enhance our manufacturing flexibility, increase our ability to scale efficiently and reinforce the quality, consistency and reliability that define HPS.”

Caution Regarding Forward-Looking Information

This press release contains forward-looking statements that involve a number of risks and uncertainties, including statements that relate to, among other things, HPS’s strategies, intentions, plans, beliefs, expectations and estimates, in connection with general economic and business outlook, prospects and trends of the industry, expected demand for products and services, product development and the Company’s competitive position, including statements regarding the expected outcome of the proposed capacity expansion and related costs of such capacity and its effects on HPS’ operational capabilities, market reach and growth profile, and the drivers thereof, as well as the expected sources of funding for such activities. Forward-looking statements can generally be identified, but not limited to, the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective” and “continue” and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. There can be no assurance that the expected initial manufacturing capacity, any future increase in capacity, related capital investments, customer demand, pricing assumptions or other operating assumptions will be achieved, proceed as currently contemplated or materialize at all. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from expectations include but are not limited to: general business and economic conditions (including but not limited to risks related to foreign currency fluctuations, changing interest rates, and the availability of external capital); risks associated with the Company’s business environment (such as risks associated with the financial condition of the data centre market, electrification and power infrastructure, oil and gas, mining and infrastructure project business); geopolitical risks; climate related risks; changes in laws and regulations; operational risks (such as risks related to existing and developing new products and services; doing business with partners and suppliers; product sales and performance; legal and regulatory proceedings; dependence on certain customers and suppliers; costs associated with raw materials, products and services; human resources; and the ability to execute strategic plans); risk associated with non-completion of the capacity expansion, risks associated with the development, equipping, commissioning and ramp-up of new manufacturing facilities, including construction or fit-out delays, cost overruns, permitting or regulatory delays, delays in the delivery or installation of equipment, availability of qualified labour, supply chain disruptions, customer demand not materializing as expected, price compression, and the facility not achieving expected production capacity, timing, efficiencies or financial returns.

The Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law.

This forward-looking information represents our views as of the date of this press release and such information should not be relied upon as representing our views as of any date subsequent to the date of this press release. We have attempted to identify important factors that could cause actual results, performance or achievements to vary from those current expectations or estimated, expressed or implied by the forward-looking information. However, there may be other factors that cause results, performance or achievements not to be as expected or estimated and that could cause actual results, performance or achievements to differ materially from current expectations.

There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those expected or estimated in such statements. Accordingly, readers should not place undue reliance on forward-looking information.

About Hammond Power Solutions Inc.

HPS enables electrification through its portfolio of power conversion, power distribution and power quality solutions, including dry-type transformers, power electronics and related products used across critical electrical infrastructure and industrial applications. The Company has manufacturing plants in North America, Europe, and Asia, and sells its products around the globe. HPS shares are listed on the Toronto Stock Exchange and trade under the symbol HPS.A.

For further information, please contact:
David Feick
Investor Relations
519-822-2441
ir@hammondpowersolutions.com

Dr. Vnuk brings substantial business and corporate development leadership experience from Sanofi, Blackstone, and Pfizer

CAMBRIDGE, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Monika Vnuk, MD, as Chief Business Officer. Dr. Vnuk will join Wave’s executive team and lead business development, corporate development, and alliance management.

“We are thrilled to welcome Dr. Vnuk to Wave in a newly created leadership role as we continue to advance our pipeline to the next stages of development. Monika’s breadth of experience, including leading global business development teams and strategic asset financing, will be meaningful as we continue to expand the potential of our differentiated RNA medicines platform and support the next phase of Wave’s growth,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences.

“Wave has built a highly versatile and differentiated RNA medicines platform with multiple therapeutic modalities translating in the clinic. I am energized to join the company at such an exciting moment, as its science and pipeline programs create broad opportunity to advance value-creating transactions with the ultimate aim of expanding Wave’s positive impact on patients. I look forward to partnering with the Wave team to help drive the company’s growth and realize the full potential of its platform and pipeline,” said Monika Vnuk, MD, Chief Business Officer of Wave Life Sciences.

Prior to joining Wave, Dr. Vnuk served as Senior Vice President, Global Head of Partnering and Business Development for Sanofi, where she led global licensing, equity investments, and alliances. Prior to Sanofi, she was Managing Director at Blackstone Life Sciences, a private life sciences investing platform, where she was focused on late-stage product financing transactions. Dr. Vnuk spent more than a decade at Pfizer in senior business development roles, including Vice President, R&D Business Development, where she led the negotiation of the successful partnership with BioNTech directed at the global co-development and distribution of COVID-19 vaccines. Before Pfizer, she worked in investment banking at Bank of America and the life sciences venture capital firm Oxford Bioscience Partners. Dr. Vnuk earned an M.D. from Boston University School of Medicine and a B.A. in Mathematics and Philosophy from Boston University.

In connection with Dr. Vnuk joining Wave, she received a stock option to purchase 375,000 shares of common stock of Wave. The equity grant was approved by Wave’s Compensation Committee and granted to Dr. Vnuk on September 21, 2026, outside of the Wave Life Sciences, Inc. Amended and Restated 2021 Equity Incentive Plan, as an inducement material to Dr. Vnuk’s commencing employment with Wave, in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option has an exercise price of $4.25 per share, the closing price on the grant date, and vests over four years with 25% vesting on September 21, 2027, and the remainder vesting in equal quarterly installments over the following three years.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Dr. Vnuk’s leadership and global experience leading business development teams and strategic asset financing, strategic partnerships, licensing, equity investments and alliances; beliefs that Dr. Vnuk’s experience will benefit the next phase of Wave’s growth; beliefs that Wave’s portfolio of RNA medicines is differentiated, best-in-class and potentially transformative; the broad potential of Wave’s RNA medicines pipeline and oligonucleotide chemistry and any benefits that may be derived from them. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release and actual results may differ materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in Wave’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827

Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com

Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com

BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 5th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Tuesday, September 29, 2026.

Panel Details
Title: “Frontiers in Neuroscience”
Date: Tuesday, September 29, 2026
Time: 10:00 AM – 10:50 AM ET

This panel will not be webcast. A recording of the panel will be available following the conference. To request a meeting or for more details about the Conference, please reach out to your institutional representative at Roth or contact cervomed@argotpartners.com. 

About CervoMed

CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology, and the Company announced alignment with the FDA on a potential registration path for neflamapimod in DLB in November 2025. Initiation of a Phase 3 trial in DLB is subject to the establishment of a partnership and/or additional financing. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA, a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.

Contacts:

Media:
Lisa Guiterman
Biongage Communications
lisa.guiterman@gmail.com
202-330-3431

Investor Relations:
Argot Partners
cervomed@argotpartners.com
212-600-1902 

ROUYN-NORANDA, Québec, Sept. 22, 2026 (GLOBE NEWSWIRE) — Falco Resources Ltd. (TSX-V – FPC) (“Falco” or the “Corporation”) is proud to announce a three-year partnership with the Collectif Territoire, an organization committed to the rehabilitation of lac Osisko and to mobilizing the community around this emblematic space in Rouyn-Noranda. As part of this partnership, Falco will contribute $30,000 per year for three years, for a total commitment of $90,000. The public announcement of this partnership is part of the activities surrounding “Les Noces d’eau” event.

For Falco, this commitment goes far beyond financial support. The Collectif Territoire’s approach, based on co-creation, territorial innovation, environmental restoration and citizen participation, is directly in line with the vision that Falco wishes to put forward in the development of Falco’s Horne 5 Project. The Corporation intends to build a lasting relationship with the Rouyn-Noranda community, in which citizens can contribute to discussions about the territory and participate in initiatives that benefit their community.

“The lac Osisko Project exemplifies the kind of initiative we want to support in Rouyn-Noranda: a collaborative and place-based approach that brings residents together around sustainable environmental and community projects. Our partnership with the Collectif Territoire is a concrete expression of the relationship that Falco seeks to build with the community,” said Hélène Cartier, Vice-President, Environment, Sustainable Development and Community Relations at Falco.

Update on Falco’s Horne 5 Project
This commitment comes as Falco’s Horne 5 Project continues to move forward. Preparatory work on the project has now been underway for more than ten years. The environmental assessment conducted by the Government of Québec is now at an advanced stage and is expected to be completed in the fall of 2026.

Since the publication of the BAPE report in January 2025, Falco has responded to several sets of questions from the Ministry of the Environment, the Fight against Climate Change, Wildlife and Parks (“MELCCFP”), particularly regarding the potential impacts of the project on community services, including health care, childcare and education services, housing, emergency services and the workforce. These issues have been the subject of in-depth analyses, particularly in the Socioeconomic Assessment (in French only) published last spring.

In addition, the potential impact of project-related vibrations on the safety and continuity of operations at the Rouyn-Noranda Radiation Oncology Centre (the “Centre”) has been thoroughly assessed by independent experts, who confirmed that the mining operations and mitigation measures proposed by Falco can be carried out safely and in a manner compatible with the activities of the Centre (see Falco’s press release dated June 16, 2026).

The completion of the environmental assessment should lead to a government decision regarding the issuance of the authorization decree for the Project (the “Decree”). Obtaining the Decree will mark a decisive step for Falco and will pave the way for the development phase of the Project after obtaining all the required permits and ministerial authorizations. In the months following the Decree, Falco will continue to carry out the required studies and investigations.

The updated feasibility study published on June 17, 2026 also confirms the extent of the anticipated benefits of Falco’s Horne 5 Project for Rouyn-Noranda and Abitibi-Témiscamingue. This project represents an initial planned investment of $1.75 billion, a mine life of at least 15 years, the creation of 500 permanent jobs as well as more than $4.4 billion in taxes and mining duties over the life of the mine.

For Falco, the development of a mining project of this magnitude must be accompanied by a lasting commitment to the community that hosts it. The partnership with the Collectif Territoire is therefore part of a broader vision: to make Falco’s Horne 5 Project not only an economic driver for the region, but also a tangible contributor to the vitality, environment and quality of life of the Rouyn-Noranda community.

To learn more about:

• Collectif Territoire’s lac Osisko Project (in French): https://www.lacosisko.ca/
• The Falco Horne 5 Project (in French): Home | Falco Horne 5
• Falco Resources: Home | Ressources Falco

About Falco

Falco is one of the largest holders of mineral claims in the province of Québec, with an extensive portfolio of properties in the Abitibi-Témiscamingue greenstone belt. Falco holds rights to approximately 60,000 hectares of land in the Noranda Camp and includes 13 former gold and base metal mine sites. Falco’s main asset is the Horne 5 Project located beneath the former Horne mine, which was operated by Noranda from 1927 to 1976 and produced 11.6 million ounces of gold and 2.5 billion pounds of copper. Osisko Gold Group Inc. (formerly Osisko Development Corp.) is Falco’s largest shareholder, with a 16.0% interest in the Corporation.

For further information, please contact:

Luc Lessard
President and Chief Executive Officer and Director
514-261-3336
info@falcores.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

MONTREAL, Sept. 22, 2026 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland”) (TSX-V: MD), in partnership with SOQUEM Inc. (“SOQUEM”), is pleased to announce the results of the 2026 exploration campaign on the Nachicapau project (Figure 1). This exploration program follows the discovery, between 2022 and 2025, of copper, gold and silver occurrences along a 4-km-long by 1.5-km-wide corridor. These new results are reported under the Strategic Alliance between Midland and SOQUEM (the “Alliance”) in the Labrador Trough in Nunavik, Quebec.

Highlights:

• Discovery of copper, gold and silver mineralization with maximum values reaching 26.8% Cu, 0.87 g/t Au, 238 g/t Ag (grab samples from boulders) associated with digenite and malachite in veins hosted in monzonite dykes.
• Two new copper, gold and silver showings on outcrops with maximum values reaching 3.03% Cu, 0.77 g/t Au, 20.0 g/t Ag (from different grab samples).
• Identification of induced polarization (“IP”) anomalies associated with Cu, Au, Ag mineral occurrences.

The 2026 sampling campaign was conducted over a period of 5 days in June, during which a total of 54 rock samples were collected. The campaign was designed to follow up on chargeability and conductivity anomalies outlined by the Orevision® induced polarization survey conducted in 2025 (figures 2 and 3).

Assay results reveal that ten (10) grab samples show grades equal to or greater than 0.10% Cu, including four (4) samples above 1.00% Cu, reaching up to 26.8% Cu. Anomalous gold values above 0.1 g/t Au are associated with these samples, while three (3) samples exhibit silver values reaching up to 238 g/t Ag. These results highlight a close relationship between Cu, Au, Ag mineralization and the presence of monzonite dykes, alkalic ultramafic units, and regional structural features. Best results obtained in grab samples are listed in Table 1.

Table 1: Best Cu, Au, Ag Assay Results from 2026 Grab Samples.

Sample Number	NAD 83 Zone 19 (m)		Type	Host Rock	Cu	Au	Ag
	UTM E	UTM N			(%)	(g/t)	(g/t)
C2130702	558492	6277160	Boulder	Monzonite dyke	26.8	0.24	238
C2130681	559665	6275540	Boulder	Monzonite dyke	14.8	0.65	112
C2130703	558467	6277165	Boulder	Monzonite dyke	7.68	0.87	57.2
C2130684	559755	6275419	Outcrop	Monzonite dyke	3.03	0.17	20.0
C2130669	559048	6276572	Outcrop	Monzonite dyke	0.59	0.77	10.3
C2130682	559665	6275540	Boulder	Monzonite dyke	0.35	0.04	2.15
C2130704	558460	6277184	Boulder	Ultramafic schist	0.28	0.07	1.53
C2130685	559643	6275552	Outcrop	Monzonite dyke	0.10	0.01	1.37
C2130668	559054	6276556	Outcrop	Monzonite dyke	0.10	0.02	1.33
C2130651	558596	6277088	Outcrop	Ultramafic schist	0.10	0.13	0.76

Digenite, Bornite and Malachite Mineralization Associated with Monzonite Dykes

The best results of the June 2026 campaign were obtained in grab samples collected in boulders, consisting of calcite-dolomite-quartz veins crosscutting a monzonite. The mineralization is characterized by the presence of centimetre-scale patches of digenite and malachite within the veins and in their selvages (Figure 4a to 4c). Hematite is a common accessory mineral and occurs as distinctive specularite crystals. The host rock is weakly deformed and systematically altered to albite, epidote and hematite.

On outcrop, these dykes crosscut, at low angles, alkalic mafic to ultramafic volcanic units of the Murdoch Formation (Figure 4d). Copper mineralization occurs in calcite-dolomite-quartz tension gashes. Sample C2130669, which graded 0.59% Cu, 0.77 g/t Au, 10.3 g/t Ag, confirms the extension of both the mineralized zone and the monzonite dyke north of the DG-12 showing discovered in 2025 (1.46% Cu, 0.14 g/t Au, 9.20 g/t Ag in a monzonite dyke).

Samples C2130681 to C2130685, collected on either side of the DG-5 showing (2.95% Cu, 0.01 g/t Au, 27.6 g/t Ag) confirm observations and interpretations made in 2025 and extend the mineralized zones associated with monzonite dykes over a distance of 150 metres. Sample C2130684, collected in a digenite-malachite vein, yielded showing-level grades of 3.03% Cu, 0.17 g/t Au and 20.0 g/t Ag.

Mineralization Associated with Mafic to Ultramafic Volcanic Units

Three (3) samples collected in ultramafic schist and intrusive units yielded anomalous Cu, Au and Ag values. Sample C2130651, which did not appear to be mineralized, yielded values of 0.10% Cu, 0.13 g/t Au, 0.76 g/t Ag, i.e. respectively 30 to 100 times higher than regional background values. This observation suggests that copper mineralization is not exclusively found in veins but may also occur disseminated within deformed and altered ultramafic units.

2025 OreVision® Induced Polarization Survey

Follow-up work on the OreVision® induced polarization survey conducted in July 2025 helped improve our understanding of the geological setting and Cu-Au-Ag mineral occurrences on the Nachicapau project. Sedimentary units (dolomite, mudstone), mafic intrusives, and ultramafic schists can be distinguished based on resistivity and chargeability contrasts. Copper mineralization is closely linked with low-resistivity (<6,000 Ohm.m) and moderate chargeability (7–14 mV/V) zones within the ultramafic schist unit and along the contact with sedimentary units (Figure 5).

Conclusions

Cu-Au-Ag mineralization on the Nachicapau project appears to be related to:

• Deformed and altered mafic to ultramafic volcanic units of the Murdoch Formation, where it occurs as disseminated digenite and malachite
• Monzonite dykes where it occurs in veins with higher-grade Cu, Au, Ag
• Intense albite-epidote-hematite alteration occurring around the veins
• Low-resistivity copper mineralization (<6,000 Ohm.m) and moderate-chargeability
  (7–14 mV/V) zones
• A deformation corridor trending N350 that affects volcanic units
• A major shear zone that marks the contact with sedimentary units

Quality Control

Rock samples from the project are analyzed at Actlabs laboratories in Ancaster, Ontario, by ICP-MS with four-acid digestion for metals and by standard fire assay on 50-gram fractions with atomic absorption finish for gold. Exploration programs are designed, and results are interpreted by Qualified Persons employing a Quality Assurance/Quality Control program consistent with industry best practices, including the use of standards and blanks for every 20 samples.

Cautionary Statements

Grab samples are selective by nature and may not be representative of mineralized zones. Mineralization observed in samples collected from boulders, outcrops and showings mentioned in this press release is not necessarily indicative of mineralization that may be found on the project mentioned in this press release.

About the Strategic Alliance with SOQUEM

The Strategic Alliance enables Midland and SOQUEM to combine their efforts and expertise to jointly explore the excellent potential for gold and strategic minerals of the vast and underexplored Labrador Trough. The area of interest defined under the Alliance is located in Nunavik. Geologically, it covers the Labrador Trough, the Rachel-Laporte Zone, and the Kuujjuaq Domain. The area of interest extends from Schefferville in the south up to approximately 100 km northwest of Kangirsuk. Executed in November 2021, the initial agreement called for investments in exploration reaching up to $4 million over a period of four (4) years, in addition to investments on the Nachicapau project.

In 2026, the parties confirmed the continuation of the Alliance with a joint annual exploration budget of $1 million (50% Midland and 50% SOQUEM) on the Malaco Mountain and Nachicapau projects.

About SOQUEM

SOQUEM is a mineral exploration company and a subsidiary of Investissement Québec. Its mission is to explore, discover, and develop Quebec’s mineral resources. SOQUEM also contributes to maintaining a strong economy in Quebec’s regions. A proud partner and ambassador for the development of Quebec’s mineral wealth, SOQUEM relies on innovation, research and strategic minerals to be well positioned for the future.

About Midland

Midland targets the mineral potential of Quebec to make the discovery of new deposits of gold and critical metals. Midland is proud to count on reputable partners such as SOQUEM Inc., Rio Tinto Exploration Canada Inc., BHP Canada Inc., Centerra Gold Inc., Barrick Gold Corporation, Agnico Eagle Mines Limited, Wallbridge Mining Company Ltd., Fresnillo plc, Electric Elements Mining Corp., Nunavik Mineral Exploration Fund and Abcourt Mines Inc. Midland prefers to work in partnership and intends to quickly conclude additional agreements in regard to newly acquired properties. Management is currently reviewing other opportunities and projects to build up the Company portfolio and generate shareholder value.

Qualified Person and Exploration Director Richard D. St-Cyr, P.Geo., reviewed and approved this press release and the Nachicapau project data as Midland’s Qualified Person (QP) within the meaning of National Instrument 43–101.

For further information, please consult Midland’s website or contact:

Gino Roger, President and Chief Executive Officer
Tel.: 450 420-5977
Fax: 450 420-5978
Email: info@midlandexploration.com
Website: https://www.midlandexploration.com/

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information (together, “forward-looking statements”) within the meaning of applicable securities laws. Forward-looking statements include statements relating to management expectations regarding the conclusion of additional agreements in regard to newly acquired properties, and other estimates and statements that describe Midland’s future plans, objectives or goals, including words to the effect that Midland or management expects a stated condition or result to occur. All statements, other than statements of historical facts, are forward-looking statements. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include, without limitation, changes in general economic conditions and conditions in the financial markets, changes in demand and prices for minerals, failure to obtain the requisite permits and approvals from government bodies and third parties, regulatory and governmental policy changes (laws and policies) and those risks set out in Midland’s public documents, including in each management discussion and analysis, filed on SEDAR+ at www.sedarplus.com. Although Midland believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by applicable law, Midland disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/cd46a469-0e89-47b9-b764-b5c3d88292ca
https://www.globenewswire.com/NewsRoom/AttachmentNg/7d66d0d4-b053-4362-ab42-1914a717bd6b
https://www.globenewswire.com/NewsRoom/AttachmentNg/f348bf20-b379-467c-adb4-4697ee130727
https://www.globenewswire.com/NewsRoom/AttachmentNg/d45930ab-89a9-4a3a-a6ee-3e76a351543a
https://www.globenewswire.com/NewsRoom/AttachmentNg/aca54b4f-ff84-4f5e-ab73-aeabc030038c

Calgary, Alberta, Sept. 22, 2026 (GLOBE NEWSWIRE) — Seegnal Inc. (TSXV:SEGN) (“Seegnal” or the “Company”), today announced that its investor relations technologies and services agreement dated March 26, 2026 (“Services Agreement”) with CapitaLynx Ltd. will conclude effective September 26, 2026.

The Services Agreement was previously disclosed in the Company’s news release dated April 1, 2026. During the engagement, the Company rebuilt its investor materials, narrative positioning and investor portal and upgraded its core investor relations assets. The Company intends to continue to use those materials, infrastructure and technologies. The Company wishes to thank CapitaLynx for its services and contributions during the engagement.

About Seegnal
Seegnal Inc. (TSXV: SEGN) is an innovative healthcare technology company dedicated to reducing medication-related harm where care begins. The Company’s SaaS-based clinical decision support platform is designed to help clinicians prescribe with greater precision by integrating patient-specific data at the point of care, including medications, laboratory results, renal function, allergies, age, and other relevant risk factors. By delivering more targeted, context-aware medication alerts within existing clinical workflows, Seegnal aims to reduce alert fatigue, support safer prescribing, and advance a more personalized standard of patient care. Seegnal’s technology is deployed across healthcare settings and is used by more than 15,000 clinicians in daily practice. For additional Company information, please visit https://investors.seegnal.com/ and follow us on LinkedIn.

Seegnal Media Contact:
Elad Bibi-Aviv
Chief Executive Officer press@seegnal.com
+972-52-533-0856
www.seegnal.com

Forward-Looking Information
This press release contains “forward-looking information” or “forward-looking statements” within the meaning of Canadian securities legislation. All statements included herein, other than statements of historical fact, including statements included in the “About Seegnal” section of this press release, are forward-looking. Generally, the forward-looking information and forward-looking statements can be identified by the use of forward-looking terminology such as “anticipate”, “believes”, “estimates”, “expects”, “intends”, “may”, “should”, “will” or variations of such words or similar expressions. More particularly, and without limitation, this press release contains forward-looking information or forward-looking statements with respect to the conclusion of the Services Agreement and the Company’s intention to continue using materials, infrastructure and technologies developed during the engagement. Seegnal cautions that all forward-looking information and forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, assumptions and expectations, many of which are beyond the control of Seegnal, including expectations and assumptions concerning Seegnal and its products as well as other risks and uncertainties, including those described in Seegnal’s filings available on SEDAR+ at www.sedarplus.ca. The reader is cautioned that assumptions used in the preparation of any forward-looking information or forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of Seegnal. The reader is cautioned not to place undue reliance on any forward-looking information or forward-looking statements. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking information and forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Seegnal does not undertake any obligation to update publicly or to revise any of the included forward-looking information or forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.